Sweden's Vimian Q3 revenue rises 15%, beats estimates
Overview
Sweden animal health group's Q3 revenue rose 15%, beating analyst expectations
Adjusted EBITA for Q3 grew 14% and beat analyst expectations
Company signed acquisition of Norfolk Medical Products after quarter end
Outlook
Vimian did not provide specific financial guidance for the current or future periods in its press release
Result Drivers
ORGANIC GROWTH - Co said double-digit organic revenue growth of 11% drove Q3 results
NICHE FOCUS - Co attributed outperformance to focus on attractive market niches and strong brand portfolio, per CEO Alireza Tajbakhsh
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | EUR 120.3 mln | EUR 115.94 mln (6 Analysts) |
Q3 Adjusted EPS | EUR 0.02 | ||
Q3 Net Income | EUR 9.30 mln | ||
Q3 Adjusted EBITA | Beat | EUR 29.2 mln | EUR 28.25 mln (4 Analysts) |
Q3 Operating Profit | EUR 20.50 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vimian Group AB is SEK40.00, about 5.1% above its October 21 closing price of SEK38.05
The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 23 three months ago
Reuters Recommended Reads
Oct 19 - France's Virbac Q3 revenue rises on strength in Both Companion Animal, Farm Animal segments
Oct 22 - Sweden's XVIVO Q3 revenue beat expectations on thoracic sales
Oct 22 - Sweden's Arjo Q3 revenue beats estimates, gross margin expands
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)